| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04412876 Details | 2022-08-17 Interventional | 3 | 0 | Duloxetine Hydr… Imipramine Enuresis Urinary Inconti… Urinary Inconti… Stress Urinary … | Failed to pass the Ministry of Science and Technology. - | |||
| NCT03812380 Details | 2022-08-17 Interventional | 3 | 62 | Magnesium citra… Osteoporosis Hypomagnesemia | The study was terminated due to a severe decrease in enrollment over the years 2020 and 2021.
The major obstacle which hindered participation of subjects was the COVID-19 pandemic. Research
was halted. Remaining study patients were withdrawn. - | |||
| NCT04102618 Details | 2022-08-15 Interventional | 1 | 26 | Atezolizumab Letrozole Trastuzumab Breast Neoplasm… Breast Cancer | Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for
the study were met. - | |||
| NCT03704714 Details | 2022-08-15 Interventional | 1/2 | - | Antibodies Antibodies, Mon… Antineoplastic … Cortisone Cyclophosphamid… Doxorubicin Immunoglobulins Liposomal doxor… Nivolumab Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Non-H… Aggressive Non-… B-Cell Non-Hodg… CD20 Positive Diffuse Large B… Intravascular L… Primary Mediast… T-Cell/Histiocy… Transformed Fol… | Protocol being amended for stats/accrual changes as per PI - | |||
| NCT03064854 2016-002815-17 Details | 2022-08-15 Interventional | 1 | 111 | Carboplatin Gemcitabine Paclitaxel Pemetrexed Spartalizumab Carcinoma, Non-… Non-small Cell … | Recruitment halted prematurely due to competitive landscape for lung cancer therapies - | |||
| NCT03759041 Details | 2022-08-12 Interventional | 2 | 203 | Vancomycin Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | Due to the lack of a clinical efficacy signal in the induction treatment phase, Seres closed
the dosing phases of open label and maintenance portions of the study. Patients who had
received prior doses were followed for safety data. - | |||
| NCT05150496 Details | 2022-08-11 Interventional | 2 | - | Vaccines COVID-19 | The plan has changed - | |||
| NCT03981744 Details | 2022-08-11 Interventional | 3 | 51 | Ustekinumab Dermatomyositis Polymyositis | The study did not meet the primary endpoint. - | |||
| NCT05079126 Details | 2022-08-10 Interventional | 2 | 18 | Trans-sodium cr… Lung Diseases Lung Diseases, … Interstitial Lu… | Due to, among other things, positive results from the 200-302 trial, the trial has been
terminated early. Resources shifted to new 200-208 GBM trial using information gained from
200-302. - | |||
| NCT04972253 Details | 2022-08-10 Interventional | 1 | 0 | Infigratinib Carcinoma, Tran… Urinary Bladder… Bladder Cancer Bladder Transit… Fibroblast Grow… | Low Accrual - | |||
| NCT01639131 Details | 2022-08-10 Interventional | 2 | 6 | Docetaxel Gemcitabine Adenocarcinoma Metastatic Colo… | - - | |||
| NCT01525069 Details | 2022-08-10 Interventional | 1 | 27 | Dexamethasone Floxuridine Gemcitabine Oxaliplatin Cholangiocarcin… Liver Neoplasms | Equipment that was used in the study was discontinued - | |||
| NCT04447235 Details | 2022-08-09 Interventional | 2 | 77 | Ivermectin Losartan COVID-19 Coronavirus Inf… Infections COVID Cancer Coronavirus Inf… | futility analysis has demonstrated no difference between arms - | |||
| NCT02974257 Details | 2022-08-09 Interventional | 2 | 36 | Thiamine Acidosis Acidosis, Lacti… Beriberi Heart Arrest Thiamine Defici… Cardiac Arrest Lactic Acidosis Shock Thiamin Deficie… | Study stopped early after consultation with DSMB - | |||
| NCT01884740 Details | 2022-08-09 Interventional | 1/2 | [1 Refs] | 13 | Bevacizumab Cetuximab Astrocytoma Diffuse Intrins… Glioblastoma Glioma Oligodendroglio… Anaplastic Astr… Brain Stem Glio… Fibrillary Astr… Glioblastoma Mu… Glioma of Brain… Mixed Oligodend… Pilomyxoid Astr… | The study was prematurely closed in December 2021 due to low accrual. This study was terminated early and participant enrollment was low, resulting in a small sample size (N=13). Having a small sample size may reduce statistical reliability and generalizability of results. | ||
| NCT04354428 Details | 2022-08-08 Interventional | 2/3 | 289 | Ascorbic Acid Azithromycin Folic Acid Hydroxychloroqu… Lopinavir Ritonavir COVID-19 SARS-CoV-2 | Low number of events contributing to primary outcome Early termination of HCQ and HCQ/AZ arms as well as lopinavir-ritonavir arms leading to small numbers of participants analyzed. | |||
| NCT02781506 Details | 2022-08-08 Interventional | 2 | 7 | Nivolumab Carcinoma Carcinoma, Rena… Metastatic Clea… | Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming
eligible for this trial and therefore, the trial was terminated. - | |||
| NCT04831450 Details | 2022-08-04 Interventional | 2 | 0 | Cemiplimab Carcinoma Carcinoma, Squa… Squamous Cell C… HNSCC Head and Neck S… Squamous Cell C… Squamous Cell C… Squamous Cell C… | Investigator Decision - | |||
| NCT03524820 Details | 2022-08-04 Interventional | 2 | 3 | Cetuximab Colonic Neoplas… Cancer of Colon | By Merck - | |||
| NCT04665115 Details | 2022-08-03 Interventional | 2 | 0 | Ibrutinib COVID-19 Communicable Di… Infections Laboratory Infe… Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, Mantl… Waldenstrom Mac… Asymptomatic CO… B-Cell Neoplasm Chronic Lymphoc… Chronic Lymphoc… Mantle Cell Lym… Marginal Zone L… Small Lymphocyt… Symptomatic COV… | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected
decline in infection rates, and the increasing use of non-ibrutinib containing BTKi therapy, we
have not been able to get support for this study - |